Advertisement

Preparation and in vitro evaluation of in situ gelling system containing lithium carbonate for parenteral administration

  • Sinan ÖzerEmail author
  • Behiye Şenel
  • Yasemin Yazan
Original Paper
  • 15 Downloads

Abstract

Lithium is the principal and the most effective drug in the treatment of bipolar disorder since the middle of the previous century. However, narrow therapeutic range and side effect profile of lithium necessitate its careful and controlled use. Patient compliance is highly needed for commercially available lithium oral product administration. Taking the affective disorder of patients into account, oral treatment seems to be inappropriate because of toxicity risk where high patient compliance is needed. The purpose of this study was to prepare an in situ gelling system which can minimize the need of patient compliance and keep lithium release in the therapeutic range. Two gel forming polymers, namely Poloxamer® 407 and Pluronic® F127, were selected owing to their biocompatibility, transparency and interaction with hydrophobic biological membranes. In situ gelling systems prepared were evaluated physicochemically at both room and body temperatures, and stability and cytotoxicity studies were performed. Gels prepared using cold method were determined to demonstrate modified release and to show the desired characteristics when compared to the commercially available preparation.

Keywords

Bipolar disorder Lithium carbonate In situ gelling system Modified release Lithuril® 

Notes

Acknowledgements

This study was supported by Anadolu University Scientific Research Projects Committee (No. 1707S447).

References

  1. 1.
    Kara K, Akarsu S, Verim S (2013) Bipolar bozuklukta nörogörüntüleme (Neuroimaging in bipolar disorder). Psikiyatride Güncel Yaklaşımlar 5(1):1–14Google Scholar
  2. 2.
    Alda M (2015) Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 20(6):661CrossRefGoogle Scholar
  3. 3.
    McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes RJ (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379(9817):721–728CrossRefGoogle Scholar
  4. 4.
    Malhi GS, Gessler D, Outhred T (2017) The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord 217:266–280CrossRefGoogle Scholar
  5. 5.
    Gulrez SKH, Al-Assaf S, Phillips GO (2011) Hydrogels: methods of preparation, characterization and applications. In: Carpi A (ed) Progress in molecular and environmental bioengineering from analysis and modeling to technology applications. Intech, Crotia, pp 117–150Google Scholar
  6. 6.
    Hennink WE, Nostrum CF (2002) Novel crosslinking methods to design hydrogels. Adv Drug Deliv Rev 54:13–36CrossRefGoogle Scholar
  7. 7.
    Hoffman AS (2002) Hydrogels for biomedical applications. Adv Drug Deliv 43:3–12CrossRefGoogle Scholar
  8. 8.
    Liu Z, Li J, Nie S, Liu H, Ding P, Pan W (2006) Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 315(1–2):12–17CrossRefGoogle Scholar
  9. 9.
    Chu K, Chen L, Xu W (2013) Preparation of a paeonol-containing temperature-sensitive in situ gel and its preliminary efficacy on allergic rhinitis. Int J Mol Sci 14(3):6499–6515CrossRefGoogle Scholar
  10. 10.
    Liu X (2015) Biodegradable thermogelling poly(organophosphazenes) and their potential biomedical applications. In: Loh XJ (ed) In-situ gelling polymers. Springer, Singapore, pp 37–67Google Scholar
  11. 11.
    Jianping Chen J, Rong Zhou R, Lin Li L, Bing Li B, Xia Zhang X, Su J (2013) Mechanical, rheological and release behaviors of a Poloxamer 407/Poloxamer 188/Carbopol 940 thermosensitive composite hydrogel. Molecules 18:12415–12425CrossRefGoogle Scholar
  12. 12.
    Park Y-J, Yong CS, Kimb H-M, Rheeb J-D, Oh Y-K, Kima C-K, Han-Gon Choi (2003) Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel. Int J Pharm 263:105–111CrossRefGoogle Scholar
  13. 13.
    Asasutjarita R, Thanasanchokpibullb S, Fuongfuchatc A, Veeranondhad S (2011) Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int J Pharm 411:128–135CrossRefGoogle Scholar
  14. 14.
    Akash MS, Rehman K (2015) Recent progress in biomedical applications of Pluronic (PF127): pharmaceutical perspectives. J Control Release 209:120–138CrossRefGoogle Scholar
  15. 15.
    USP 41 (2018) The United States pharmacopeia and national formulary 2018, including supplement 1: (February 2018). Supplement 2: (June 2018). United States Pharmacopeial Convention Inc., USAGoogle Scholar
  16. 16.
    ICH Harmonised Tripartite Guideline (2005) Validation of analytical procedures: text and methodology Q2(R1). In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 19 March 2018
  17. 17.
    Khateb KA, Ozhmukhametova EK, Mussin MN, Seilkhanov SK, Rakhypbekov TK, Lau WM, Khutoryanskiy VV (2016) In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery. Int J Pharm 502(1–2):70–79CrossRefGoogle Scholar
  18. 18.
    Tsuji H, Horii F, Hyon SH, Ikada Y (1991) Stereocomplex formation between enantiomeric poly(lactic acid)s. 2. Stereocomplex formation in concentrated solutions. Macromolecules 24(10):2719–2724CrossRefGoogle Scholar
  19. 19.
    Srividya B, Cardoza RM, Amin PD (2001) Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 73(2–3):205–211CrossRefGoogle Scholar
  20. 20.
    Makwana SB, Patel VA, Parmar SJ (2016) Development and characterization of in situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharma Sci 6:1–6CrossRefGoogle Scholar
  21. 21.
    Nie S, Hsiao WW, Pan W, Yang Z (2011) Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomed 6:151–166Google Scholar
  22. 22.
    Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S (2010) DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12(3):263–271CrossRefGoogle Scholar
  23. 23.
    Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L (2016) In vitro cell based assays: cell viability assays. In: Sittampalam GS, Coussens NP, Brimacombe K et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, IndianapolisGoogle Scholar
  24. 24.
    Ruel-Garièpy E, Leroux JC (2004) In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm 58:409–426CrossRefGoogle Scholar
  25. 25.
    Almeida H, Amaral MH, Lobao P, Lobo JMS (2014) In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 19(4):400–412CrossRefGoogle Scholar
  26. 26.
    EMA (European Medicines Agency) (2015) Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use. Committee for Medicinal Products for Human Use (CHMP). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/11/WC500196733.pdf. Accessed 20 Nov 2017
  27. 27.
    Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T (2007) Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv 14(8):507–515CrossRefGoogle Scholar
  28. 28.
    Ward WK, Castle JR, Branigan DL, Massoud RG, El Youssef J (2012) Discomfort from an alkaline formulation delivered subcutaneously in humans. Clin Drug Investig 32(7):433–438CrossRefGoogle Scholar
  29. 29.
    Babu JMS, Sevukarajan M, Thamizhvanan K, Naveenkumar B, Reddy BS, Vivekananda U, Shyamkumar V (2013) Evaluation of physiochemical and anti-tubercular activity of co-crystal of isoniazid with methyl paraben. Int J Innov Drug Discov 3(1):10–27Google Scholar
  30. 30.
    Methyl 4-hydroxybenzoate, Sigma Reference Standard, Sigma-AldrichGoogle Scholar
  31. 31.
    Pol E, Coumans FAW, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, Sturk A, van Leeuwen TG, Nieuwland R (2014) Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 12(7):1182–1192CrossRefGoogle Scholar
  32. 32.
    Gürsoy AZ (2012) Enjeksiyonluk dozaj şekilleri, diğer steril çözeltiler, kan ve kan ürünleri (Injectable dosage forms, other sterile solutions, blood and blood products). In: Gürsoy AZ (ed) Farmasötik teknoloji- temel konular ve dozaj şekilleri. Aktif Matbaa ve Reklam Hizmetleri SanTicLtdŞti, İstanbul, pp 213–230Google Scholar
  33. 33.
    Özdamar K (1997) Paket Programları ile İstatistiksel Veri Analizi (Çok Değişkenli Analizler) (Statistical data analysis using software-multivariant analyses). Kaan Kitabevi, EskişehirGoogle Scholar
  34. 34.
    Lopes-Ramos CM, Pereira TC, Dogini DB, Gilioli R, Lopes-Cendes I (2016) Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado–Joseph disease. Braz J Med Biol Res 49(12):1–7CrossRefGoogle Scholar
  35. 35.
    Allagui MS, Vincent C, Gaubin Y, Croute F (2007) Lithium toxicity and expression of stress-related genes or proteins in A549 cells. Biochim Biophys Acta (BBA) Mol Cell Res 1773(7):1107–1115CrossRefGoogle Scholar
  36. 36.
    Arranja A, Schroder AP, Schmutz M, Waton G, Schosseler F, Mendes E (2014) Cytotoxicity and internalization of Pluronic micelles stabilized by core cross-linking. J Control Release 196:87–95CrossRefGoogle Scholar
  37. 37.
    Gavrilova YS, Bgatova NP, Solov’eva AO, Trifonova KE, Lykov AP, Borodin YI, Konenkov VI (2016) Target cells for lithium in different forms within a heterogeneous hepatocarcinoma-29 population. Cell Tissue Biol 10(4):284–289CrossRefGoogle Scholar
  38. 38.
    Güven UM (2016) Antihistaminik etkili oftalmik kontrollü salım gösteren farklı sistemler üzerinde çalışmalar (Studies on different ophthalmic controlled release systems with antihistaminic activity). Ph.D. Dissertation, Anadolu ÜniversitesiGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Technology, Faculty of PharmacyAnadolu UniversityEskisehirTurkey
  2. 2.Department of Pharmaceutical Biotechnology, Faculty of PharmacyAnadolu UniversityEskisehirTurkey

Personalised recommendations